Drug Trial Radar · NCT01572727
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Last checked: Nov 20, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Aug 2012
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
PaclitaxelDrug
intravenous paclitaxel 80 mg/m2 per week given until progression
BKM120 matching placeboDrug
Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
BKM120Drug
Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Assessed by Local Investigator's Assessment (Phase ll)Time frame: Every 8 weeks from randomization until disease progression up to 10 months after futility was analyzed
Locations
112 sites in 22 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers SC
Chandler, Arizona
Arizona Oncology Associates Dept of Oncology
Phoenix, Arizona
Highlands Oncology Group Dept of Highlands Oncology Grp
Fayetteville, Arkansas
California Cancer Care Marian Speciality
Greenbrae, California
Rocky Mountain Cancer Centers RMCC Hale Pkwy
Greenwood Village, Colorado
H. Lee Moffitt Cancer Center & Research Institute SC
Tampa, Florida
Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2)
Atlanta, Georgia
Northwest Georgia Oncology Center NW Georgia Onc
Marietta, Georgia
University of Kansas Cancer Center Univ Kansas 2
Kansas City, Kansas
Norton Healthcare, Inc.
Louisville, Kentucky
Washington University School of Medicine Regulatory
St Louis, Missouri
University of Nebraska Medical Center Unv Nebraska Med Ctr (2)
Omaha, Nebraska
University of New Mexico Cancer Research Center Dept of Univ New Mexico
Albuquerque, New Mexico
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
Troy, New York
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1
Columbus, Ohio
University of Oklahoma Health Sciences Center OUHSC 2
Oklahoma City, Oklahoma
Northwest Cancer Specialists Vancouver Loc
Portland, Oregon
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology
Dallas, Texas
University of Texas Southwestern Medical Center Harry Hines
Dallas, Texas
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio
San Antonio, Texas
Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA
Reston, Virginia
Novartis Investigative Site
Sydney, New South Wales, Australia
Novartis Investigative Site
Geelong, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Charleroi, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Ottignies, Belgium
Novartis Investigative Site
Sint-Niklaas, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Brno, Czech Republic, Czechia
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.